Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2015-2017

ABSTRACT

Primary objective: The primary objective of this study is to assess the effect of Ginkgo biloba L. leaf extract (IDN 5933) in comparison to placebo in human subjects treated at therapeutic doses for 6 months on the level of DNA damage and genomic instability, measured with the Comet Assay and the Micronucleus assay, respectively . Secondary objective: The secondary objective of this study is to provide a preliminary assessment of the safety of Ginkgo biloba L. leaf extract (IDN 5933) in human subjects treated at therapeutic doses in term of adverse drug reaction, hepatotoxicity, genotoxicity. Detailed Description The study will be a randomised clinical trial comparing subjects receiving twice-daily doses of either 120-mg of Ginkgo biloba L. leaf extract (IDN 5933) or placebo for a 6 months period. Primary Endpoints: - DNA Damage assessed with the Comet assay as proportion of DNA in the tail. - Micronucleus frequency (MN) in peripheral blood lymphocytes (Frequency per 1000 binucleated cells). Secondary Endpoints: - Complete clinical assessment at the beginning and at the end of the study. - Occurrence of Adverse drug reactions in individuals treated with GBE or placebo. - Liver functions will be monitored according to biological laboratory examinations and clinical symptoms. A subgroup of individuals will be monitored also for genetic parameters concerning expression patterns of genes putatively associated to early events of HCC carcinogenesis Clinical and biological parameters will be measured in the study groups at the beginning (T0) and at the end of the study (T2). More... »

URL

https://clinicaltrials.gov/show/NCT03004508

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Primary objective: The primary objective of this study is to assess the effect of Ginkgo biloba L. leaf extract (IDN 5933) in comparison to placebo in human subjects treated at therapeutic doses for 6 months on the level of DNA damage and genomic instability, measured with the Comet Assay and the Micronucleus assay, respectively . Secondary objective: The secondary objective of this study is to provide a preliminary assessment of the safety of Ginkgo biloba L. leaf extract (IDN 5933) in human subjects treated at therapeutic doses in term of adverse drug reaction, hepatotoxicity, genotoxicity.\n\nDetailed Description\nThe study will be a randomised clinical trial comparing subjects receiving twice-daily doses of either 120-mg of Ginkgo biloba L. leaf extract (IDN 5933) or placebo for a 6 months period. Primary Endpoints: - DNA Damage assessed with the Comet assay as proportion of DNA in the tail. - Micronucleus frequency (MN) in peripheral blood lymphocytes (Frequency per 1000 binucleated cells). Secondary Endpoints: - Complete clinical assessment at the beginning and at the end of the study. - Occurrence of Adverse drug reactions in individuals treated with GBE or placebo. - Liver functions will be monitored according to biological laboratory examinations and clinical symptoms. A subgroup of individuals will be monitored also for genetic parameters concerning expression patterns of genes putatively associated to early events of HCC carcinogenesis Clinical and biological parameters will be measured in the study groups at the beginning (T0) and at the end of the study (T2).", 
    "endDate": "2017-01-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03004508", 
    "keywords": [
      "frequency", 
      "cell maintenance", 
      "Carcinogenesis", 
      "comet assay", 
      "gene", 
      "liver function", 
      "T2", 
      "preliminary assessment", 
      "genotoxicity", 
      "clinical assessment", 
      "biological parameter", 
      "randomised study", 
      "Genomic Instability", 
      "occurrence", 
      "individual", 
      "daily", 
      "randomised clinical trial", 
      "tail", 
      "primary endpoint", 
      "subgroup", 
      "genetic parameter", 
      "beginning", 
      "peripheral blood lymphocyte", 
      "secondary objective", 
      "hepatotoxicity", 
      "T0", 
      "human subject", 
      "assay", 
      "safety", 
      "study group", 
      "clinical symptom", 
      "Drug-Related Side Effect and Adverse Reaction", 
      "Ginkgo biloba", 
      "period", 
      "DNA", 
      "cell", 
      "antioxidant", 
      "comparison", 
      "early event", 
      "proportion", 
      "placebo", 
      "therapeutic dose", 
      "laboratory examination", 
      "expression pattern", 
      "primary objective", 
      "DNA damage", 
      "Mn", 
      "micronucleus", 
      "secondary endpoint", 
      "extract"
    ], 
    "name": "Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A Randomised Study Versus Placebo", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03004508"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00023.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.18887.3e", 
        "type": "Organization"
      }
    ], 
    "startDate": "2015-07-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1073/pnas.182425199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006119463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.tox.2014.10.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025524601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.mrrev.2013.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032327530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/carcin/bgl177", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042944414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/0929867311320130008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069163105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078726402", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12906-018-2080-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100559052", 
          "https://doi.org/10.1186/s12906-018-2080-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12906-018-2080-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100559052", 
          "https://doi.org/10.1186/s12906-018-2080-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03004508"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03004508'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03004508'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03004508'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03004508'


 

This table displays all metadata directly associated to this object as RDF triples.

90 TRIPLES      16 PREDICATES      72 URIs      59 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03004508 schema:about anzsrc-for:3053
2 schema:description Primary objective: The primary objective of this study is to assess the effect of Ginkgo biloba L. leaf extract (IDN 5933) in comparison to placebo in human subjects treated at therapeutic doses for 6 months on the level of DNA damage and genomic instability, measured with the Comet Assay and the Micronucleus assay, respectively . Secondary objective: The secondary objective of this study is to provide a preliminary assessment of the safety of Ginkgo biloba L. leaf extract (IDN 5933) in human subjects treated at therapeutic doses in term of adverse drug reaction, hepatotoxicity, genotoxicity. Detailed Description The study will be a randomised clinical trial comparing subjects receiving twice-daily doses of either 120-mg of Ginkgo biloba L. leaf extract (IDN 5933) or placebo for a 6 months period. Primary Endpoints: - DNA Damage assessed with the Comet assay as proportion of DNA in the tail. - Micronucleus frequency (MN) in peripheral blood lymphocytes (Frequency per 1000 binucleated cells). Secondary Endpoints: - Complete clinical assessment at the beginning and at the end of the study. - Occurrence of Adverse drug reactions in individuals treated with GBE or placebo. - Liver functions will be monitored according to biological laboratory examinations and clinical symptoms. A subgroup of individuals will be monitored also for genetic parameters concerning expression patterns of genes putatively associated to early events of HCC carcinogenesis Clinical and biological parameters will be measured in the study groups at the beginning (T0) and at the end of the study (T2).
3 schema:endDate 2017-01-01T00:00:00Z
4 schema:keywords Carcinogenesis
5 DNA
6 DNA damage
7 Drug-Related Side Effect and Adverse Reaction
8 Genomic Instability
9 Ginkgo biloba
10 Mn
11 T0
12 T2
13 antioxidant
14 assay
15 beginning
16 biological parameter
17 cell
18 cell maintenance
19 clinical assessment
20 clinical symptom
21 comet assay
22 comparison
23 daily
24 early event
25 expression pattern
26 extract
27 frequency
28 gene
29 genetic parameter
30 genotoxicity
31 hepatotoxicity
32 human subject
33 individual
34 laboratory examination
35 liver function
36 micronucleus
37 occurrence
38 period
39 peripheral blood lymphocyte
40 placebo
41 preliminary assessment
42 primary endpoint
43 primary objective
44 proportion
45 randomised clinical trial
46 randomised study
47 safety
48 secondary endpoint
49 secondary objective
50 study group
51 subgroup
52 tail
53 therapeutic dose
54 schema:name Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A Randomised Study Versus Placebo
55 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03004508
56 schema:sdDatePublished 2019-03-07T15:27
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N2b9960474c544716a2aaf2ae0d6a75d0
59 schema:sponsor https://www.grid.ac/institutes/grid.18887.3e
60 schema:startDate 2015-07-01T00:00:00Z
61 schema:subjectOf sg:pub.10.1186/s12906-018-2080-5
62 https://app.dimensions.ai/details/publication/pub.1078726402
63 https://doi.org/10.1016/j.mrrev.2013.10.001
64 https://doi.org/10.1016/j.tox.2014.10.013
65 https://doi.org/10.1073/pnas.182425199
66 https://doi.org/10.1093/carcin/bgl177
67 https://doi.org/10.2174/0929867311320130008
68 schema:url https://clinicaltrials.gov/show/NCT03004508
69 sgo:license sg:explorer/license/
70 sgo:sdDataset clinical_trials
71 rdf:type schema:MedicalStudy
72 N2b9960474c544716a2aaf2ae0d6a75d0 schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
75 rdf:type schema:DefinedTerm
76 sg:pub.10.1186/s12906-018-2080-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100559052
77 https://doi.org/10.1186/s12906-018-2080-5
78 rdf:type schema:CreativeWork
79 https://app.dimensions.ai/details/publication/pub.1078726402 schema:CreativeWork
80 https://doi.org/10.1016/j.mrrev.2013.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032327530
81 rdf:type schema:CreativeWork
82 https://doi.org/10.1016/j.tox.2014.10.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025524601
83 rdf:type schema:CreativeWork
84 https://doi.org/10.1073/pnas.182425199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006119463
85 rdf:type schema:CreativeWork
86 https://doi.org/10.1093/carcin/bgl177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042944414
87 rdf:type schema:CreativeWork
88 https://doi.org/10.2174/0929867311320130008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069163105
89 rdf:type schema:CreativeWork
90 https://www.grid.ac/institutes/grid.18887.3e schema:Organization
 




Preview window. Press ESC to close (or click here)


...